International Psoriasis Council

subscribe
Search
Advancing Knowledge. Enhancing Care.
subscribe
Search

Advancing Knowledge. Enhancing Care.

Psoriasis News

THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results

Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.

Read More
Tuesday, April 25, 2023
Commentary -Tiago Torres

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.

Read More
Tuesday, March 28, 2023
Commentary -Peter van de Kerkhof headshot

Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial

Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.

Read More
Thursday, December 15, 2022
Filip Rob Commentary graphic

Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial

The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.

Read More
Friday, October 14, 2022
Blog - Commentary - Alexander Egeberg - graphic

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.

Read More
Wednesday, August 31, 2022

Commentary: Psoriasis comprehensive review

In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and comprehensive review of the current pieces of knowledge on psoriasis. It is a very well-written review covering all aspects of psoriasis

Read More
Tuesday, May 25, 2021

New Resources

Psoriasis Treatment and Chronic Infections (Webinar 2, 2023 Series)

VIEW

Psoriasis and Cancer: Epidemiologic Association (Webinar 2, 2023 Series)

VIEW

Psoriasis Treatment and Cancer: New Perspectives (Webinar 2, 2023 Series)

VIEW

Subscribe to the IPC Newsletter

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.